Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

Budde Lihua E.; Sehn Laurie H.; Assouline Sarit; Flinn Ian W.; Isufi Iris; Yoon Sung-Soo; Kim Won-Seog; Matasar Matthew J.; Nastoupil Loretta J.; Santiago Raoul; Koh Youngil; Hernandez Genevive; Li Chi-Chung; Kulkarni Priya R.; McCall Bruce; McClellan Scott; Yin Shen; Gupta Vinita; Chu Yu-Waye; Bartlett Nancy L.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

【24h】

Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

机译：MosuneTuzumab，全长双特异性CD20 / CD3抗体，在复发/难治性B细胞非霍奇金淋巴瘤（NHL）中显示临床活性：临时安全性和疗效结果来自阶段1研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共4页
作者
Budde Lihua E.; Sehn Laurie H.; Assouline Sarit; Flinn Ian W.; Isufi Iris; Yoon Sung-Soo; Kim Won-Seog; Matasar Matthew J.; Nastoupil Loretta J.; Santiago Raoul; Koh Youngil; Hernandez Genevive; Li Chi-Chung; Kulkarni Priya R.; McCall Bruce; McClellan Scott; Yin Shen; Gupta Vinita; Chu Yu-Waye; Bartlett Nancy L.;
展开▼
作者单位

City Hope Natl Med Ctr Duarte CA USA;

BC Canc Ctr Lymphoid Canc Vancouver BC Canada;

Jewish Gen Hosp Montreal PQ Canada;

Tennesse Oncol Sarah Cannon Res Inst Nashville TN USA;

Yale Univ New Haven CT USA;

Seoul Natl Univ Hosp Seoul South Korea;

Samsung Med Ctr Seoul South Korea;

Mem Sloan Kettering New York NY USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

Jewish Gen Hosp Montreal PQ Canada;

Seoul Natl Univ Hosp Seoul South Korea;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Washington Univ Sch Med Siteman Canc Ctr St Louis MO USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study [J] . Budde Lihua E., Sehn Laurie H., Assouline Sarit, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：MosuneTuzumab，全长双特异性CD20 / CD3抗体，在复发/难治性B细胞非霍奇金淋巴瘤（NHL）中显示临床活性：临时安全性和疗效结果来自阶段1研究
2. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial [J] . Raymund Buhmann, Stanglmaier Michael, Hess Juergen, Journal of Translational Medicine . 2013,第1期

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案，非随机，不受控制，剂量递增的I / II试验阶段
3. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study [J] . Stathis Anastasios, Flinn Ian W., Madan Sumit, Investigational new drugs. . 2018,第5期

机译：IMGN529的安全性，耐受性和初步活性，CD37靶向抗体 - 药物缀合物，复发或难治性B细胞非霍奇金淋巴瘤的患者：一种剂量升级，我研究
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Immunotherapy with FBTA05 (Bi20) a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven open-label non-randomized uncontrolled dose-escalating Phase I/II-trial [O] . Raymund Buhmann, Stanglmaier Michael, Hess Juergen, 2013

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案非随机不受控制剂量递增的I / II试验阶段
6. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial [O] . 2013

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案，非随机，不受控制，剂量递增的I / II试验阶段

Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

著录项

相似文献

相关主题

期刊订阅